Burning Rock Announces 2026 Annual General Meeting to be Held on December 22, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Burning Rock Biotech (NASDAQ: BNR) will hold its annual general meeting on December 22, 2026, at its Shanghai office. The meeting starts at 10:30 a.m. local time. Proposed resolutions cover ratifying Ernst & Young Hua Ming as auditor for the fiscal year ending December 31, 2026, authorizing directors to determine auditor remuneration, and re-electing Zhihong (Joe) Zhang and Wendy Hayes as directors.
The record date is November 17, 2026, at the close of business, New York time. ADS holders wishing to vote the underlying Class A shares must give voting instructions to Citibank, the depositary. The board recommends voting in favor of the proposals.
Key Figures
- AGM date
- December 22, 2026
- Annual general meeting
- Record date
- November 17, 2026
- Determines shareholders entitled to receive AGM notice
Key Terms
next generation sequencing technical
form 20-f regulatory
ordinary resolution regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
GUANGZHOU, China, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 22, 2026 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company’s website, within Investors Relation section, at https://ir.brbiotech.com.
The AGM will be held for the following proposals:
- as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2026 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
- as an ordinary resolution, THAT Zhihong (Joe) Zhang and Wendy Hayes be re-elected as directors of the Company; and
- as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
The board of directors of the Company fully supports these proposals and recommends that shareholders and holders of American depositary shares (“ADSs”) vote in favor of these proposals.
The board of directors of the Company has fixed the close of business on November 17, 2026 (New York time) as the record date for determining the shareholders entitled to receive notice of the AGM or any adjournment or postponement thereof. Holders of record of the Company’s Class A ordinary shares or Class B ordinary shares, each with a par value of US
The board of directors of the Company fully supports the proposed resolutions and recommends that shareholders and holders of ADSs vote in favor of the proposed resolutions.
The Company has filed its annual report on Form 20-F containing the complete audited financial statements and the report of auditors for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed on the Company’s website at https://ir.brbiotech.com, and on SEC’s website at http://www.sec.gov.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can Burning Rock BNR ADS holders vote at the 2026 annual general meeting?
ADS holders of record at the close of business on November 17, 2026, New York time, must give voting instructions to Citibank, the ADS depositary, to exercise voting rights for their underlying Class A ordinary shares. The meeting notice and proxy form are available in the investor relations section at https://ir.brbiotech.com.